The Wuhan Mingyi Tumor Hospital International Alliance serves as a crucial strategic fulcrum for the Sino-US Saiaojin Tumor Chain Group's expansion into Central China and nationwide reach. Leveraging the group's core technologies in the biomedical field, global industrial resources, and international operational expertise, the alliance focuses on precision tumor diagnosis and treatment, as well as the translation of cutting-edge cell therapy technologies. It aims to establish an international tumor medical innovation system that integrates clinical practice, scientific research, teaching, and industry.